ASCO 2010: New Treatments for CML

Dr. Jorge Cortes discusses new data on bosutinib, a new tyrosine kinase inhibitor for CML.

Related Content:

Chronic Myeloid Leukemia

FDA Grants Breakthrough Therapy Designation to Asciminib for 2 CML Indications

FDA Approves Ponatinib To Treat Adult Patients with Resistant/Intolerant Chronic-Phase CML

Study Finds Treatment-Free Remission Not Impaired by Low-Dose TKIs for Patients with CML